Pipeline Report

Updated February 1st, 2026

BuyandBill.com Analytics Pro Features

Unlock Full Access to
BuyandBill.com Analytics

Upgrade to BuyandBill.com Pro to access this report and the complete suite of analytics tools.

You attempted to open: Drug Pipeline Report
10+ Years of Historical Pricing Data
Unlimited Access to All Drug Pages
Comparative & Historical Drug Pricing Reports
PriceDoctoRx Self-Administered Drug Pricing
Medicare & Medicaid Claims Data
Drug Pipeline Report
Check Out New Features
Comparative Pricing Reports
Go Back
View Our Subscription Options

Search

Descriptive Alt Text

Filters

Showing results 1,601–1,608 of 4,419
Manufacturer ▼ Drug Name Indication Stage Status Route of Administration Drug Class
Eli Lilly and Company Tanezumab Osteoarthritis NDA Filing Withdrawn Subcutaneous Orthopedic
Eli Lilly and Company Rezpegaldesleukin (LY3471851) - (REZOLVE-AD) Atopic Dermatitis Phase 2b Data Released Subcutaneous Immunology
Eli Lilly and Company VTX2735 Healthy volunteers, cryopyrin-associated periodic syndrome (CAPS) Phase 2 Ongoing oral Genetic Disorder
Eli Lilly and Company Solanezumab Inherited Alzheimer's disease Phase 2/3 Intravenous Genetic Disorder
Eli Lilly and Company Kisunla (donanemab) - (TRAILBLAZER-ALZ 2) Alzheimer’s disease BLA Filing Ongoing Intravenous Neurology
Eli Lilly and Company (Z)-endoxifen with abemaciclib (VERZENIO) - (EVANGELINE) Pre-menopausal women w/ early-stage estrogen receptor positive and Human Epidermal Growth Factor Receptor 2 negative breast cancer Phase 2 Data Released Oral Oncology
Eli Lilly and Company Tanezumab Cancer pain Phase 3 Subcutaneous Oncology
Eli Lilly and Company Tirzepatide - (SUMMIT) Heart failure with preserved ejection fraction (HFpEF) and obesity Phase 3 Data Released Subcutaneous Cardiology
1…199200201202203…553
Your trusted source for drug reimbursement data and buy-and-bill insights.
Platform
Resources
Tools
Search Drugs
Newsletter
Reimbursement updates, drug pricing news.
© 2026 BuyandBill.com, All Rights Reserved.
HCPCS Level II codes and descriptors are approved and maintained jointly by the alpha-numeric editorial panel (consisting of CMS, America's Health Insurance Plans, and Blue Cross and Blue Shield Association). CPT® codes and descriptions are copyright American Medical Association (AMA). All rights reserved.